Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

59.05 +0.87 (+1.49%)
Streaming Delayed Price Updated: 3:17 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
News headline image
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally? ↗
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
News headline image
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today ↗
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. 
Via InvestorPlace
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
Analyzing CRISPR Therapeutics's Unusual Options Activity ↗
Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus... 
Via Benzinga
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Is Sinking Today ↗
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Tumbling Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
News headline image
20 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-... 
Via Benzinga
News headline image
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall? ↗
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
News headline image
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Fell 10.4% Last Month ↗
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading. 
Via The Motley Fool
News headline image
These 3 Top Healthcare Stocks Are Screaming Buys Right Now ↗
If the market crashes these companies could be insulated. 
Via The Motley Fool
News headline image
Biotech Playbook Revisited As Technicals Weaken ↗
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
News headline image
3 Explosive Biotech Stocks That Could 10X in 10 Years ↗
They're leaders in therapeutic areas with massive growth potential. 
Via The Motley Fool
News headline image
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market ↗
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
News headline image
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought ↗
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover. 
Via The Motley Fool
News headline image
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics ↗
Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech. 
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Stock Help You Retire a Millionaire? ↗
A crowded field could take years to thin out. 
Via The Motley Fool
News headline image
Vaccine Victory ↗
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
News headline image
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
News headline image
Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics ↗
Currently trading at a very reasonable multiple, CRSP stock is an undeniable buy. 
Via InvestorPlace
News headline image
Why CRISPR Therapeutics Stock Fell 25.2% in July ↗
The stock dropped roughly $40 per share over the course of the month. 
Via The Motley Fool
News headline image
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
News headline image
Better Buy: Vertex vs. CRISPR ↗
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run. 
Via The Motley Fool
News headline image
CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today ↗
Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate. 
Via InvestorPlace
News headline image
Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over... 
Via Benzinga
News headline image
Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.